# BPC-157 TB-500 FAQ: the Wolverine Blend, Answered From the Literature > BPC-157 TB-500 questions answered from the research record: identity, mechanism, the synergy gap, pharmacokinetics, safety, and FDA 503A status. Direct, cited, no guidance. The questions people actually ask about the Wolverine blend, with direct answers cited to the published literature — and the gaps marked as gaps. ## Identity and mechanism These BPC-157 TB-500 answers cover what each peptide is and how it works. ### What Is the Wolverine Peptide Blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack" [4]. It is not a single chemical entity and not an approved product; commercial vials carry a combined mass but no clinically validated ratio [4]. ### What Are BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 — the cytoskeletal, cell-migration component [3][8]. ### What Is the Difference Between BPC-157 and TB-500? BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein, acting as a cytoprotective and angiogenic signal [1]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4, acting as a cytoskeletal actin-sequestration signal [3]. They are structurally unrelated, with distinct mechanisms [4]. ### How Does TB-500 Work? TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it and regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3]. Structural work on a thymosin beta-4-actin complex established the dual-end capping basis of this mechanism [3]. ### How Does BPC-157 Work Compared to TB-500? BPC-157 is reported to up-regulate VEGFR2 with downstream Akt-eNOS angiogenic signaling, modulate the nitric-oxide system, and sensitize tendon fibroblasts via growth-hormone-receptor up-regulation [1][2]. TB-500 instead sequesters G-actin to regulate cell migration [3]. The pathways are largely distinct. ## Combination, evidence, and efficacy These answers cover why the two are paired and what the evidence does — and does not — show. ### Why Are BPC-157 and TB-500 Combined? The pairing rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies a cytoskeletal actin-sequestration signal driving cell migration [4]. The two are described as complementary but largely non-overlapping; no controlled combination study has defined a synergistic dose, ratio, or endpoint [9]. ### Is the Combination Synergy Actually Demonstrated? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together; a 2025 systematic review of BPC-157 (36 studies, only 1 human) makes no mention of TB-500 or combination use [9]. "Synergy" is a theoretical extrapolation from each peptide's separate mechanism. ### Are There Human Trials of the Combination? No. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies [11], and "TB-500" human data are for full-length thymosin beta-4 — Phase 1 intravenous studies [6][7] — not the heptapeptide. ### What Does Tendon and Ligament Research Show? In rodent models, BPC-157 accelerated healing of a transected Achilles tendon and improved ligament and tendon-to-bone healing [1]; thymosin beta-4 enhanced medial collateral ligament healing [4]. These are animal findings for the individual constituents, not human or combination data. ### What Does Muscle-Recovery Research Show? Animal studies report BPC-157 aiding recovery of crushed muscle and muscle-to-bone reattachment, and thymosin beta-4 acting as a myoblast chemoattractant [4]. Effects are preclinical; no controlled human recovery data exist for the blend. ### Do Both Peptides Promote Angiogenesis? Yes, by distinct routes in animal and cell models: BPC-157 via VEGFR2 up-regulation and the VEGFR2-Akt-eNOS pathway [2], and thymosin beta-4 via endothelial migration [4]. Both have been reported to increase vessel formation and tissue perfusion preclinically. ### What Does the Most Recent Research Say? Recent reviews (2024-2026) consolidate strong preclinical promise for BPC-157 while stressing extremely limited human data; a 2025 systematic review [9] and a 2026 narrative review [10] conclude the evidence is low-tier with scarce human safety data and no controlled combination study. ### What Do Recent Reviews Conclude? Recent peer-reviewed reviews describe BPC-157 as showing promise for musculoskeletal recovery but only from level IV-V evidence with no clinical safety data, treat it as investigational [9][11], and note that unapproved musculoskeletal peptides including BPC-157 and TB-500 operate largely outside regulatory oversight [10]. ## Pharmacokinetics and handling These answers report what studies recorded, never a protocol for use. ### What Is the Half-Life of BPC-157 and TB-500? BPC-157's elimination half-life was reported under 30 minutes in a rat and beagle-dog PK study [5]; no validated human half-life exists for either constituent at research doses, and none for the blend. Human full-length thymosin beta-4 showed dose-proportional pharmacokinetics [6][7], but no specific half-life is established for the TB-500 heptapeptide. ### How Do You Reconstitute a BPC-157 / TB-500 Blend? Both constituents are supplied as lyophilized powders for research use and are reconstituted in bacteriostatic or sterile water and refrigerated [4]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed; this describes research handling only, not human-use guidance. ### How Often Should BPC-157 and TB-500 Be Administered in Research? There is no validated dose or frequency for the blend. The underlying rodent studies used intraperitoneal dosing schedules per model [1][4]; community "loading then maintenance" blend protocols have no controlled-trial basis. ### How Much BPC-157 and TB-500 Has Been Used in Studies? No validated weekly dose exists for the blend. Animal-model reference points include BPC-157 around 10 µg/kg and 10 ng/kg in rodents [1], and full-length thymosin beta-4 across a wide range in animal studies [4]; these are not human dosing recommendations. ### Can BPC-157 and TB-500 Be Taken Orally Instead of Injected? BPC-157 is studied as a "stable gastric" peptide, and oral blend products are marketed, but they lack validated pharmacokinetics [5]. Predominant research-community routes are subcutaneous and intramuscular; the underlying efficacy studies for both peptides were largely intraperitoneal [1][4]. ### Can BPC-157 and TB-500 Be Mixed in One Syringe? A common research practice is to reconstitute the two peptides separately or in a shared vial, but no controlled study validates a co-formulation, ratio, or combined dose [4]. Identity and purity of unregulated "Wolverine" material are unverified outside formal studies. ## Safety and regulatory status These answers cover the safety signals and the regulatory record. ### What Are the Reported Safety Concerns? Long-term human safety is unknown for both constituents and for the blend. A key concern is that thymosin beta-4 is implicated in tumor metastasis and angiogenesis, so its pro-migratory, pro-angiogenic properties could theoretically support tumor progression [4]; combining two unapproved peptides doubles the uncertainty, and a 2026 review notes potential for serious harm across this class [10]. ### Does TB-500 Promote Tumor Growth? Thymosin beta-4 has been implicated in tumor metastasis and angiogenesis in cancer models [4]. This is a theoretical safety signal rather than evidence of cancer causation in humans, but the same pro-angiogenic, pro-migratory properties that aid repair could, in principle, support tumor progression. ### Is the Wolverine Blend Legal? Neither BPC-157 nor TB-500 is an FDA-approved drug, both are currently in FDA's 503A Category 2 (restricting routine compounding access as the record stands), and both are prohibited in sport by WADA [12]. The full picture is on the [Wolverine legal status and 503A category](/legal-status) page. ### Can BPC-157 Be Obtained From a Compounding Pharmacy? BPC-157 is currently in FDA's 503A Category 2 — identified as potentially presenting significant safety risks, effective with the September 29, 2023 list update — which is not within FDA's enforcement-discretion policy, restricting routine compounding access now [12]. It is also on the scheduled July 2026 PCAC agenda as a candidate under evaluation [14]. ### What Is the FDA 503A Status of the Wolverine Components? Both constituents are unapproved research substances, and both are currently in FDA's 503A Category 2 (effective September 29, 2023) [12]. Both are also on the scheduled July 23-24, 2026 PCAC agenda as candidates "being considered for inclusion on the 503A Bulks List" — a discussion under evaluation, not a listing decision [14]. --- A distilled field-record of the BPC-157 and TB-500 literature — each peptide pressed as its own cited specimen, its 503A access status read first, with no clinic behind the folio and nothing here prescribed or sold.